Cue Biopharma, Inc.
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
CUE$20.14+7.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
| Three Months EndedJune 30, | Six Months EndedJune 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Collaboration revenue | $7,877 | $2,954 | $13,563 | $3,374 |
| Operating expenses: | ||||
| General and administrative | 46,565 | 3,679 | 50,717 | 7,852 |
| Research and development | 49,007 | 7,910 | 55,904 | 16,457 |
| Gain on lease termination | — | — | (10) | — |
| Total operating expenses | 95,572 | 11,589 | 106,611 | 24,309 |
| Loss from operations | (87,695) | (8,635) | (93,048) | (20,935) |
| Other income (expense): | ||||
| Interest income | 157 | 198 | 336 | 368 |
| Interest expense | (5) | (45) | (9) | (172) |
| Loss on issuance of liability-classified warrants and related issuance costs | (90,011) | — | (90,011) | — |
| Changes in fair value of financial instruments | 24,487 | — | 24,487 | — |
| Total other income (expense), net | (65,372) | 153 | (65,197) | 196 |
| Net loss | $(153,067) | $(8,482) | $(158,245) | $(20,739) |
| Net loss per common share – basic and diluted | $(24.14) | $(2.67) | $(28.39) | $(7.33) |
| Weighted average common shares outstanding – basic and diluted | 6,340,844 | 3,181,980 | 5,574,272 | 2,828,568 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.